Mucosal healing in ulcerative colitis: Where do we stand?

Gionata Fiorino, Monica Cesarini, Amedeo Indriolo, Alberto Malesci

Research output: Contribution to journalArticlepeer-review


Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation affecting the colonic mucosa, that can extend to the whole large bowel. The severity of mucosal lesions directly reflects the disease activity and severity and may be prognostic for an aggressive behavior of the pathology. Remission, is usually defined as resolution of symptoms. Recently, mucosal healing (MH) has emerged as an important end point of any shortterm medical therapy for IBD. It may predict long-term remission and may impact on the natural history of the disease in Crohn's disease (CD), while data in UC patients are still limited. This review of the literature is focused on the recent evidence on the impact of medications on MH in UC and on the impact of MH on the natural course of UC.

Original languageEnglish
Pages (from-to)1417-1423
Number of pages7
JournalCurrent Drug Targets
Issue number10
Publication statusPublished - Sep 2011


  • Colonoscopy
  • Inflammatory bowel disease
  • Medical therapy
  • Mucosal healing
  • Ulcerative colitis

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine


Dive into the research topics of 'Mucosal healing in ulcerative colitis: Where do we stand?'. Together they form a unique fingerprint.

Cite this